Sage Therapeutics Income Statement

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	1,294	1,105	957.84	858.41
Revenue Growth (YoY)	17.11%	15.34%	11.58%	-
Cost of Revenue	909.54	788.56	691.77	640.52
Gross Profit	384.22	316.22	266.07	217.89
Selling, General & Admin	124.6	104.66	98.28	85.06
Other Operating Expenses	86.87	65.73	62.76	57.37
Operating Expenses	218.71	186.82	178.19	155.59
Operating Income	165.51	129.4	87.88	62.3
Interest Expense	-6.95	-6.84	-4.82	-6.55
Interest & Investment Income	1.69	1.27	1.11	0.26
Currency Exchange Gain (Loss)	5.1	3.38	1.49	2.93
Other Non Operating Income (Expenses)	-0.24	-0.13	-0	-0
Pretax Income	165.11	127.09	85.65	58.95
Income Tax Expense	42.74	32.72	22.16	16.15
Net Income	122.38	94.37	63.5	42.8
Net Income to Common	122.38	94.37	63.5	42.8
Net Income Growth	29.68%	48.61%	48.38%	-
Shares Outstanding (Basic)	13	13	13	13
Shares Outstanding (Diluted)	13	13	13	13
EPS (Basic)	9.51	7.33	4.93	3.32
EPS (Diluted)	9.51	7.33	4.93	3.32
EPS Growth	29.70%	48.68%	48.49%	-
Free Cash Flow	27.07	6.79	-18.07	79.32
Free Cash Flow Per Share	2.10	0.53	-1.40	6.16
Gross Margin	29.70%	28.62%	27.78%	25.38%
Operating Margin	12.79%	11.71%	9.17%	7.26%
Profit Margin	9.46%	8.54%	6.63%	4.98%
Free Cash Flow Margin	2.09%	0.61%	-1.89%	9.24%
EBITDA	169.31	141.99	100.3	73.53
EBITDA Margin	13.09%	12.85%	10.47%	8.57%
D&A For EBITDA	3.8	12.59	12.43	11.22
EBIT	165.51	129.4	87.88	62.3
EBIT Margin	12.79%	11.71%	9.17%	7.26%
Effective Tax Rate	25.88%	25.75%	25.87%	27.40%
Revenue as Reported	1,301	1,109	962.59	862.45
Advertising Expenses	10.79	12.14	9.51	4.23

Source: S&P Global Market Intelligence. Standard template. Financial Sources.